about
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-...
Read More
10.50
0.50
(5.00%)
892.1K
XNAS Volume
High volume+gain today
XNAS 10 Mar, 2026 5:30 PM (EDT)
Medium Financial Strength
Expensive Valuation
Technically Bullish
Expensive Rocket
These stocks have good momentum, but are expensive with average financials
View Similar
Embed DVM
Immatics N.V Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..